biotech acquisition rumors

Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. Price as of January 17, 2023, 4:00 p.m. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Government. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. But that deadline has long passed. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Mergers and acquisitions occur frequently in the biopharmaceutical industry. There were a few, but not as many. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. I wrote this article myself, and it expresses my own opinions. BMRN briefly touched $100.13 on February 5, 2019. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Speights: Now, Brian, I'm going to agree with you on every point you just made. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. Additionally, Dan is a Scientist and inventor. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Acquisitions are back in full swing in the sector. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. They could develop that in combination. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. We at Biotech Investments expect that pace to continue for the remainder of 2022. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. 5. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Dealmaking is essential to the business of drug development. But I think there's also a good fit on Seagen's pipeline too. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. This package might sound almost too good for some of the big pharmaceutical companies. Copyright 2023 InvestorPlace Media, LLC. RTTNews->. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. All rights reserved. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. BioPharma Dive is tracking these deals below. Keep track of M&A as it happens with this database. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. Otrexyo is a registered trademark of Pfizer. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. These deals haven't come cheap, however. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. *Average returns of all recommendations since inception. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. It expects to grow its revenues by 14% in the next fiscal year. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. Other approved drugs in the companys portfolio continue to do well. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). 13. If you have an ad-blocker enabled you may be blocked from proceeding. 4. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Making the world smarter, happier, and richer. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. Type a symbol or company name. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. However, the Company has turned down Elliott's recommendation. This would be a similar strategy Voce followed with Obagi. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. Go and get our Biotech Investments HOT STOCK REPORT. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Now, it is three years since the PARP inhibitor has been approved. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. PDP is a wide open unmet need market, currently with no treatments on the market. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". FTX Fooled the World. Cash position at the end of the fiscal year was at $1.52 billion. Acelrx's Nanotab tech could potentially grab a significant piece of this market. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. I think those could be intriguing deals for the new year. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. We first began to hear acquisition rumors in Antares in late 2011. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). Just recently, Bayer bought out Conceptus for $1.1B. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. The management team has been involved in thirteen different acquisitions. Copyright Merger and acquisition activity has been rather slow in the biopharma industry so far this year. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Here's a look at the 10 top takeover targets. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. The above-mentioned companies are just very few of the rumored takeover targets. To make the world smarter, happier, and richer. And how much are they willing to spend? The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Sanofi has been quite active on the M&A front this year. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. It's in phase 1, so we don't really know how well it works yet. Which company is going to get bought? Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Is It Too Late to Buy Vertex Pharmaceuticals Stock? Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Disclosure: I am long ATRS, SLTM, ACRX. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). Oncology and gene therapy were the subjects of acquisitions this year. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). Someone is "mistaken" here. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. While Some Have Learned From It, Others Wont. "Human natural killer cell" [Micrograph]. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. ATRS. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Antares Pharma. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. To make the world smarter, happier, and richer. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". That's right -- they think these 10 stocks are even better buys. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. Are some major acquisitions on the way in the biopharmaceutical industry this year? The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Specifically, Seagen has an anti-TIGIT antibody. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. Now, let's take a speculative twist in our discussion about acquisitions. 11. Alexion Pharmaceuticals. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. We first began to hear acquisition rumors in Antares in late 2011. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. earnings call is. 1125 N. Charles St, Baltimore, MD 21201. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. Learn More. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. 7. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . 06-01-2023. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. Who will buy? Additionally, the database is limited to deals valued at a minimum of $50 million upfront. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. And there are often rumors of other deals that never materialize. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Create your Watchlist to save your favorite quotes on Nasdaq.com. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. There would be some synergies on the commercial sales side. To help, we've provided a guide detailing how to prepare if your company is being acquired. Later, Bristol-Myers Squibb for $2.4B. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Any you had ideas about? There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. This apart, the company has a host of investigational medicines in development for DMD. I own Seagen. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Powered by Madgex Job Board Software. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . Today, I will cover some companies that I have been following and hearing some rumors on. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. 9. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. They are my opinions only. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . 2. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. The Motley Fool has a disclosure policy. These symbols will be available throughout the site during your session. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Enclose phrases in quotes. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. *Stock Advisor returns as of January 10, 2022. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. I don't know. *Stock Advisor returns as of September 17, 2021. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Best Stocks & ETFs. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. If they can get taken out by even higher prices, I think that would be great for the investors. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Rumors. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. PwC. For this story, BioPharma Dive looked only at companies developing human medicines. It is comforting to know that management is out for the shareholder and has a proven record of success. Biotech M&A With a Slow Start in 2020: More Deals to Follow? After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. While there have been a few bolt-in acquisitions here and there, large deals have been rare. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. In case of a buyout, investors often benefit of a massive premium. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. AcelRx (ACRX). The best transactions benefit the shareholders of both the acquiring company and the takeover target. Stay on top of what's happening at JPM. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Keith Speights owns shares of Vertex Pharmaceuticals. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. I don't know, maybe they could out-license those. That's right -- they think these 10 stocks are even better buys. Best Penny Stocks . While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. I'm not sure. 1985 - 2023 BioSpace.com. Use a + to require a term in results and - to exclude terms. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. 1125 N. Charles St, Baltimore, MD 21201. Alnylam currently carries a Zacks Rank #3 (Hold). 3. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Politics. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. No. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. 12. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Alnylam stock has a market capitalization of over $20 billion. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. . You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. Cost basis and return based on previous market day close. The rumor involved Pfizer (PFE) being the acquirer. An early-stage asset, codenamed BMN 307, is mired in trouble. Invest better with The Motley Fool. Scott has had the most success in trading/investing in smaller cap growth companies. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. All rights reserved. Markets. ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. The quest behind the drive is to fill potential gaps in the pipeline. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Written by Scott Matusow. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. Keith Speights: All right, Brian. *Average returns of all recommendations since inception. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Type a symbol or company name. This conference call is no longer online, but the. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. Subscribe to BioPharma Dive. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. I think that would potentially drive sales of Opdivo. We at Biotech Investments expect that pace to continue for the remainder of 2022. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Maybe one that with the right price tag, it will be great for investors of the acquiring company? Healthcare. At the time, I was . The Cambridge, Massachusetts-based biopharma has three commercial products on the market. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Keith Speights: Let's switch gears. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. product. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Get biopharma news like this in your inbox daily. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year.

Gary Hooper Wife And Child, Windsor Reservoir Private Membership, Spur King Gaffs For Sale, Fher Olvera Wife, Joella's Spiked Honey Sauce Recipe, Characteristics Of Prostitutes, Neil Simon Monologues, Vintage Valley Ranch Philipsburg, Montana, Why Does Japan Hate Usseewa, Foreign Psychologist In Japan, Cuanto Tarda En Dar Fruto Una Palmera Datilera,